An Open Label Study to Assess the Safety and Efficacy of COR-003(2S 4R-Ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

An Open Label Study to Assess the Safety and Efficacy of COR-003(2S 4R-Ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Recruiting
1 years - 99 years
All
Phase 3
2 participants needed
1 Location

Brief description of study

The purpose of this clinical research study is to find out if the drug COR-003 is safe and has beneficial effects in patients who have Cushings disease and to determine the most effective dosage for each individual subject. . COR-003 is taken in pill form twice a day. The study will involve 90 people with Cushings disease in North America and in certain European countries. The study will begin with a screening period followed by a dose finding phase, lasting 2-16 weeks, to determine the most effective and tolerable maximum dose for an individual subject. Once the appropriate dose has been determined, subjects will take the study medicine for 6 months. At the end of six months, subjects will be followed for another 6 months so that more information can be collected.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Cushing syndrome
  • Age: 1 years - 99 years
  • Gender: All
Updated on 19 Feb 2024. Study ID: 819642

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.